Jaguar Health, Inc. (JAGX)
NASDAQ: JAGX · Real-Time Price · USD
2.560
-0.150 (-5.54%)
Jun 27, 2025, 10:44 AM - Market open
Jaguar Health Employees
Jaguar Health had 49 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
49
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$235,755
Profits / Employee
-$810,816
Market Cap
3.39M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
JAGX News
- 1 day ago - Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset - Accesswire
- 2 days ago - Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs - Accesswire
- 2 days ago - Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026 - Accesswire
- 4 days ago - Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer - Accesswire
- 10 days ago - Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts - Accesswire
- 16 days ago - First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs - Accesswire
- 17 days ago - REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners' Spring 2025 Spotlight Series - Accesswire
- 18 days ago - Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer - Accesswire